Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8573096 | 1.00 | GAA (0.32) | GAACYP2C19ADORA3ADORA2AADORA2B | |
| SCHEMBL9876380 | 1.00 | GAA (0.32) | GAACYP2C19ADORA3ADORA2AADORA2B | |
| SCHEMBL3078362 | 0.87 | GAA (0.37) | GAACYP2C19 | |
| SCHEMBL27813307 | 0.84 | — | — | |
| SCHEMBL12306342 | 0.84 | ADORA3 (0.31) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL3078360 | 0.84 | — | — | |
| SCHEMBL27706231 | 0.84 | — | — | |
| SCHEMBL16091103 | 0.84 | — | — | |
| SCHEMBL27726845 | 0.81 | ADORA3 (0.32) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL27813308 | 0.81 | ADORA3 (0.32) | ADORA3ADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103275104-A | Preparation method of ceftobiprole and ceftobiprole medocaril | SUZHOU MINGYUE MEDICAL TECHNOLOGY CO LTD | 2013-09-04 | — | — | CN | claimed |
| EP-0111934-B1 | CEPHALOSPORIN DERIVATIVES AND PROCESS FOR THEIR PREPARATION | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-08-17 | — | — | EP | claimed |
| WO-2019070973-A1 | CEPHEM COMPOUNDS WITH LATENT REACTIVE GROUPS | GLADIUS PHARMACEUTICALS CORPORATION (CA) | 2019-04-11 | — | — | WO | disclosed |
| US-20150111853-A1 | CEPHALOSPORIN COMPOSITIONS AND METHODS OF MANUFACTURE | MERCK SHARP & DOHME CORP. | 2015-04-23 | — | — | US | disclosed |
| US-9006421-B2 | Cephalosporin compositions and methods of manufacture | CUBIST PHARMACEUTICALS, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| WO-2014152763-A1 | CEPHALOSPORIN COMPOSITIONS AND METHODS OF MANUFACTURE | CUBIST PHARMACEUTICALS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140274958-A1 | CEPHALOSPORIN COMPOSITIONS AND METHODS OF MANUFACTURE | MERCK SHARP & DOHME LLC | 2014-09-18 | — | — | US | disclosed |
| US-20140274958-A1 | CEPHALOSPORIN COMPOSITIONS AND METHODS OF MANUFACTURE | MERCK SHARP & DOHME LLC | 2014-09-18 | — | — | US | disclosed |
| CN-103275104-A | Preparation method of ceftobiprole and ceftobiprole medocaril | SUZHOU MINGYUE MEDICAL TECHNOLOGY CO LTD | 2013-09-04 | — | — | CN | disclosed |
| EP-0481441-B1 | Novel cephem compounds, their preparation processes and antibacterial agents | KYORIN SEIYAKU KK (JP) | 1996-12-11 | — | — | EP | disclosed |
| US-5244892-A | Pseudomonas | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1993-09-14 | — | — | US | disclosed |
| EP-0481441-A2 | Novel cephem compounds, their preparation processes and antibacterial agents | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1992-04-22 | — | — | EP | disclosed |
| EP-0111934-B1 | CEPHALOSPORIN DERIVATIVES AND PROCESS FOR THEIR PREPARATION | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-08-17 | — | — | EP | disclosed |
| EP-0111934-A2 | Cephalosporin derivatives and process for their preparation | HOECHST AKTIENGESELLSCHAFT (DE) | 1984-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140274958-A1 | CEPHALOSPORIN COMPOSITIONS AND METHODS OF MANUFACTURE | CYP3A7, SEPTIN7, PEPD | GAA 2760/4885CYP2C19 122/4885ADORA3 3363/4885 |
| US-20150111853-A1 | CEPHALOSPORIN COMPOSITIONS AND METHODS OF MANUFACTURE | CYP3A7, SEPTIN7, PEPD | GAA 2760/4885CYP2C19 122/4885ADORA3 3363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.